PUBLIC COMPANY
save$RXRXRECURSION PHARMACEUTICALS, INC.
$RXRX4.0700-1.45%Salt Lake City, UT, USupdated 20h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 12Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- phase2Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
- phase2A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
- phase2The Clostridioides Difficile Trial of REC-3964
- phase3Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
- phase2The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (4)
- Apr 22, 26cGibson Christopher · director40,000 sh
- Apr 22, 26cGibson Christopher · director40,000 sh
- Apr 7, 26cGibson Christopher · director40,000 sh
- Apr 7, 26cGibson Christopher · director40,000 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
Where RECURSION PHARMACEUTICALS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 6Immunology & Inflammation 1
News
- Former Recursion CEO Chris Gibson joins Dimension as operating partnerIn a decade of leading and building Recursion Pharmaceuticals, Chris Gibson attempted to bridge the worlds of biology and technology. Now, months after leaving Recursion, he's joining a VC firm tha…endpoints · 2mo ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that